{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:10:19Z","timestamp":1738887019946,"version":"3.37.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n      A 67-year-old female patient with a muscle-invasive, non-metastatic urothelial bladder cancer (UC) (pT2 G3 cN0 cM0) developed metachronous metastases within 6 months after radical cystectomy with ileal conduit urinary diversion.\n    <\/jats:p><jats:p>\n      After a good primary response to platinum-based chemotherapy, treatment was switched to the immune checkpoint inhibitor (ICI) pembrolizumab due to progressive disease. Subsequently the patient underwent selective internal radiotherapy (SIRT) of the liver and received vinflunine as well as a re-challenge with pembrolizumab.\n    <\/jats:p><jats:p>\n      Two years after the initial diagnosis, rapid disease progression ultimately led to a switch to 5th line therapy with enfortumab vedotin (EV), which had only been approved in the United States at that time. The antibody-drug conjugate was well tolerated by the patient after dose reduction to 1.0 mg\/ kg body weight. Simultaneous irradiation of newly occurring precardiac, hepatic and cerebral metastases were necessary. After 10 months of therapy with EV, tumour regression was observed accompanied with good symptom control.\n    <\/jats:p><jats:p>\n      The presented case illustrates the efficacy and tolerability of EV in a heavily pre-treated patient with metastatic UC (mUC).\n    <\/jats:p>","DOI":"10.1055\/a-2148-5799","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:24:05Z","timestamp":1700007845000},"page":"71-76","source":"Crossref","is-referenced-by-count":0,"title":["Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer"],"prefix":"10.1055","volume":"56","author":[{"given":"Melanie","family":"Klee","sequence":"additional","affiliation":[{"name":"Department of Urology, Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck, Lubeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Christine","family":"Roesch","sequence":"additional","affiliation":[{"name":"Department of Urology, Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck, Lubeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Eggers","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medizinische Hochschule Hannover, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[{"name":"Urology, MHH, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[{"name":"Department of Urology, Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck, Lubeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Urology, Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck, Lubeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of Bladder Cancer","volume":"8","author":"K Saginala","year":"2020","journal-title":"Med Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"H von der Maase","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"J Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"AV Balar","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"DF Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"3","author":"T Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study","volume":"35","author":"AB Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00345-018-2486-1","article-title":"SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer","volume":"37","author":"AS Merseburger","year":"2019","journal-title":"World J Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","volume":"26","author":"F Facchinetti","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"DM Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"JE Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1756287220980192","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab Vedotin in urothelial cancer","volume":"12","author":"M Alt","year":"2020","journal-title":"Ther Adv Urol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"T Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Y Fradet","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.21037\/tau-21-123","article-title":"Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review","volume":"10","author":"VS Koshkin","year":"2021","journal-title":"Transl Androl Urol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"PM Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.6004\/jadpro.2020.11.4.8","article-title":"Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin","volume":"11","author":"KS Hanna","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"S 06","key":"ref19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.19.02105","article-title":"Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"38","author":"JE Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1002\/onco.13827","article-title":"The Rapidly Evolving Landscape of First. Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review","volume":"26","author":"J Lavoie","year":"2021","journal-title":"The Oncologist"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2148-5799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T23:51:29Z","timestamp":1738885889000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2148-5799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":19,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2148-5799","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"type":"print","value":"0001-7868"},{"type":"electronic","value":"1438-8820"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}